HRP20170346T1 - Postupak za poticanje angiogeneze, prokrvljenosti, ili obnove krvnih žila ili za inhibiciju angiogeneze tumora - Google Patents
Postupak za poticanje angiogeneze, prokrvljenosti, ili obnove krvnih žila ili za inhibiciju angiogeneze tumora Download PDFInfo
- Publication number
- HRP20170346T1 HRP20170346T1 HRP20170346TT HRP20170346T HRP20170346T1 HR P20170346 T1 HRP20170346 T1 HR P20170346T1 HR P20170346T T HRP20170346T T HR P20170346TT HR P20170346 T HRP20170346 T HR P20170346T HR P20170346 T1 HRP20170346 T1 HR P20170346T1
- Authority
- HR
- Croatia
- Prior art keywords
- molecule
- antisense molecule
- sequence
- disease
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007052114A DE102007052114B4 (de) | 2007-10-30 | 2007-10-30 | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| EP08844273.6A EP2217704B1 (de) | 2007-10-30 | 2008-10-30 | Verfahren zur förderung der angiogenese, vaskularisierung oder gefässreparatur oder zur hemmung der tumorangiogenese |
| PCT/DE2008/001759 WO2009056116A1 (de) | 2007-10-30 | 2008-10-30 | Verfahren zur förderung der angiogenese, vaskularisierung oder gefässreparatur oder zur hemmung der tumorangiogenese |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170346T1 true HRP20170346T1 (hr) | 2017-04-21 |
Family
ID=40375407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170346TT HRP20170346T1 (hr) | 2007-10-30 | 2008-10-30 | Postupak za poticanje angiogeneze, prokrvljenosti, ili obnove krvnih žila ili za inhibiciju angiogeneze tumora |
| HRP20171874TT HRP20171874T1 (hr) | 2007-10-30 | 2017-12-04 | Postupak za poticanje angiogeneze, vaskularizacije ili obnavljanje krvnih žila ili za inhibiciju angiogeneze tumora |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171874TT HRP20171874T1 (hr) | 2007-10-30 | 2017-12-04 | Postupak za poticanje angiogeneze, vaskularizacije ili obnavljanje krvnih žila ili za inhibiciju angiogeneze tumora |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8258113B2 (enExample) |
| EP (3) | EP2217704B1 (enExample) |
| JP (4) | JP5898843B2 (enExample) |
| CA (1) | CA2704290C (enExample) |
| CY (2) | CY1120360T1 (enExample) |
| DE (1) | DE102007052114B4 (enExample) |
| DK (2) | DK2684955T3 (enExample) |
| ES (2) | ES2618203T3 (enExample) |
| HR (2) | HRP20170346T1 (enExample) |
| HU (2) | HUE037494T2 (enExample) |
| LT (2) | LT2684955T (enExample) |
| NO (1) | NO2684955T3 (enExample) |
| PL (2) | PL2684955T3 (enExample) |
| PT (2) | PT2684955T (enExample) |
| SI (2) | SI2684955T1 (enExample) |
| WO (1) | WO2009056116A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| JP2010500011A (ja) | 2006-08-08 | 2010-01-07 | ガンサー ハートマン | ５’リン酸オリゴヌクレオチドの構造および使用 |
| DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
| US20130302293A1 (en) * | 2010-11-11 | 2013-11-14 | Keith A. Webster | Compositions, cells, kits and methods for autologous stem cell therapy |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
| EP2864482A4 (en) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
| EP3563859B1 (en) | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| ES2606636T3 (es) * | 2013-01-24 | 2017-03-24 | Pierre Fabre Médicament S.A.S. | Composición que comprende un antagomir encapsulado |
| MX364814B (es) | 2013-03-15 | 2019-05-08 | Miragen Therapeutics Inc | Nucleosidos biciclicos unidos en puente. |
| US11439668B2 (en) | 2014-05-23 | 2022-09-13 | JangoBio, LLC | Methods to differentiate stem cells into hormone-producing cells |
| US11253549B2 (en) | 2014-05-23 | 2022-02-22 | JangoBio, LLC | Methods to rebalance the hypothalamic-pituitary-gonadal axis |
| CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| US20160122762A1 (en) * | 2014-10-27 | 2016-05-05 | University Of Iowa Research Foundation | Methods of treating atherosclerosis |
| HK1249108A1 (zh) * | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| CN107586784B (zh) * | 2016-07-08 | 2020-08-25 | 田小利 | 一种分离的rnasek基因及其在制备抗血管衰老药物中的应用 |
| WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| EP3612191B1 (en) | 2017-04-19 | 2026-03-11 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| US11674141B2 (en) * | 2018-02-28 | 2023-06-13 | National University Corporation Tokyo Medical And Dental University | Ischemic-lesion-site-specific gene therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| EP2471924A1 (en) * | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Methods and compositions involving microRNA |
| US20090209621A1 (en) * | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
| ES2425387T3 (es) * | 2006-07-13 | 2013-10-15 | The Ohio State University Research Foundation | Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre |
| US8466117B2 (en) * | 2006-07-28 | 2013-06-18 | The Johns Hopkins University | Compositions and methods for modulating angiogenesis |
| WO2008070082A2 (en) * | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
| WO2009004632A2 (en) * | 2007-07-05 | 2009-01-08 | Yeda Research And Development Co. Ltd. | Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation |
| BRPI0813527A2 (pt) * | 2007-07-18 | 2014-12-30 | Univ Colorado | Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham |
| DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
-
2007
- 2007-10-30 DE DE102007052114A patent/DE102007052114B4/de active Active
-
2008
- 2008-10-30 ES ES08844273.6T patent/ES2618203T3/es active Active
- 2008-10-30 ES ES13179144.4T patent/ES2651287T3/es active Active
- 2008-10-30 US US12/739,876 patent/US8258113B2/en active Active
- 2008-10-30 PL PL13179144T patent/PL2684955T3/pl unknown
- 2008-10-30 CA CA2704290A patent/CA2704290C/en not_active Expired - Fee Related
- 2008-10-30 EP EP08844273.6A patent/EP2217704B1/de active Active
- 2008-10-30 WO PCT/DE2008/001759 patent/WO2009056116A1/de not_active Ceased
- 2008-10-30 DK DK13179144.4T patent/DK2684955T3/en active
- 2008-10-30 NO NO13179144A patent/NO2684955T3/no unknown
- 2008-10-30 HR HRP20170346TT patent/HRP20170346T1/hr unknown
- 2008-10-30 PT PT131791444T patent/PT2684955T/pt unknown
- 2008-10-30 EP EP13179144.4A patent/EP2684955B1/de active Active
- 2008-10-30 PL PL08844273T patent/PL2217704T3/pl unknown
- 2008-10-30 LT LTEP13179144.4T patent/LT2684955T/lt unknown
- 2008-10-30 SI SI200831894T patent/SI2684955T1/en unknown
- 2008-10-30 EP EP13179146.9A patent/EP2684956B1/de active Active
- 2008-10-30 PT PT88442736T patent/PT2217704T/pt unknown
- 2008-10-30 SI SI200831774A patent/SI2217704T1/sl unknown
- 2008-10-30 DK DK08844273.6T patent/DK2217704T3/en active
- 2008-10-30 LT LTEP08844273.6T patent/LT2217704T/lt unknown
- 2008-10-30 JP JP2010531412A patent/JP5898843B2/ja not_active Expired - Fee Related
- 2008-10-30 HU HUE13179144A patent/HUE037494T2/hu unknown
- 2008-10-30 HU HUE08844273A patent/HUE031559T2/hu unknown
-
2012
- 2012-08-08 US US13/569,786 patent/US8912158B2/en active Active
-
2014
- 2014-06-05 JP JP2014116545A patent/JP2014196317A/ja active Pending
- 2014-07-31 US US14/448,119 patent/US9279123B2/en active Active
-
2016
- 2016-02-10 US US15/040,487 patent/US9862949B2/en active Active
- 2016-06-24 JP JP2016125260A patent/JP2016199565A/ja active Pending
-
2017
- 2017-02-22 CY CY20171100245T patent/CY1120360T1/el unknown
- 2017-12-04 HR HRP20171874TT patent/HRP20171874T1/hr unknown
- 2017-12-06 CY CY20171101283T patent/CY1120226T1/el unknown
- 2017-12-14 JP JP2017239230A patent/JP2018083817A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Piccoli et al. | Non-coding RNAs as modulators of the cardiac fibroblast phenotype | |
| JP6751465B2 (ja) | クロモン誘導体の上皮間葉移行抑制活性を利用した線維症予防及び治療用医薬組成物としての新規用途 | |
| JP2011500858A5 (enExample) | ||
| JP2013525330A5 (enExample) | ||
| ES2651287T3 (es) | Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral | |
| CN106978415B (zh) | 转运rna片段及其应用 | |
| WO2017077329A3 (en) | Nucleic acids, peptides and methods | |
| CN109414448A (zh) | 用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子 | |
| WO2012065027A3 (en) | Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases | |
| ECSP088701A (es) | Compuestos de pirimidinil sulfonamida que inhiben la adhesión de los leucocitos mediada por vla-4 | |
| EP4008786A3 (en) | The mirna-212/132 family as a therapeutic target | |
| BR112012010866A2 (pt) | "nova construção de vetor viral para síntese específica otimizada contínua de dopa por neurônios in vivo". | |
| EP3924371A4 (en) | GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE | |
| WO2009044392A3 (en) | Novel sirna structures | |
| WO2020071519A1 (ja) | 間葉系幹細胞の動員に基づく疾患治療薬 | |
| Xu et al. | Angiogenic lncRNAs: a potential therapeutic target for ischaemic heart disease | |
| JPWO2020149395A5 (enExample) | ||
| KR101671675B1 (ko) | 베이지 및 갈색 지방세포 분화 유도용 조성물 및 이의 방법 | |
| JP7189587B2 (ja) | メチル化関連酵素ｈａｔ１とｋａｔ８の阻害薬 | |
| Chen et al. | MicroRNA-132 improves myocardial remodeling after myocardial infarction. | |
| EP3983551A4 (en) | CONSTRUCTION OF DNA TO TARGET THERAPEUTIC MOLECULES TO DISEASE TISSUE BY IMMUNE CELLS | |
| González Caminero | Generación y caracterización de organoides de corazón genéticamente modificados: estudio de su potencial antifibrótico y mejoras del modelo | |
| CN104208660B (zh) | 低分子量碱性成纤维细胞生长因子lmw fgf2的应用 | |
| Aday et al. | 198 microRNA-17 As The Target of Immobilized Vascular Endothelial Growth Factor in Endothelial Cell Survival Under Ischaemic Conditions | |
| Ferreiro et al. | 702P SEPN1/SELENON-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCA |